I see one area that is still a problem:
"Pile: Will Afrezza still be priced at a premium to competing mealtime insulins?
Castagna: We will strive to be more innovative around how payors will evaluate our brand value proposition because you can’t compare a Tesla and a Prius and claim that because they are both electric they should cost the same on a retail or discounted basis. The experience a person gets by sitting in and driving these two cars is completely different despite the fact they both get you from point A to point B."
In short---yes it will still be priced at a premium to competing mealtime insulins. That is not the best way to rapidly gain market-share.